Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Esperion (NASDAQ: ESPR) and Spero Therapeutics Inc (NASDAQ: SPRO) with bullish sentiments.

Esperion (NASDAQ: ESPR)

In a report released today, Chris Shibutani from Cowen & Co. assigned a Buy rating to Esperion (NASDAQ: ESPR), with a price target of $95. The company’s shares opened today at $38.32, close to its 52-week low of $30.95.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 13.8% and a 44.2% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

Currently, the analyst consensus on Esperion is Moderate Buy and the average price target is $85.36, representing a 122.8% upside.

In a report issued on May 16, UBS also maintained a Buy rating on the stock with a $75 price target.

See today’s analyst top recommended stocks >>

Spero Therapeutics Inc (NASDAQ: SPRO)

Cowen & Co. analyst Ritu Baral assigned a Buy rating to Spero Therapeutics Inc (NASDAQ: SPRO) today. The company’s shares opened today at $11.20, close to its 52-week low of $9.66.

According to TipRanks.com, Baral is a top 25 analyst with an average return of 35.5% and a 57.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Currently, the analyst consensus on Spero Therapeutics Inc is Strong Buy and the average price target is $28.33, representing a 152.9% upside.

In a report issued on May 11, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $28 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.